Prothena(PRTA)

Focus: Prothena is a Dublin-headquartered public biotech focused on monoclonal antibodies targeting neurology and immunology indications. The company is in mid-to-late stage development with a 241% R&D intensity and $619M in cash reserves.

Neurology Immunology

Profile data last refreshed 2h ago · AI intelligence enriched 1w ago

Funding Stage

PUBLIC

Open Jobs

About Prothena

AI assessmentNot Hiring

No open roles listed right now. Follow Prothena to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthStrong

Pipeline

Late-stage

3 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$91M

Pipeline & Clinical Trials

Cutaneous Autonomic Pilomotor Testing to Unveil the Role of Neuropathy Progression in Early Parkinso

Parkinson's Disease

N/A

Clinical Trials (1)

NCT03043768Cutaneous Autonomic Pilomotor Testing to Unveil the Role of Neuropathy Progression in Early Parkinson's Disease

N/A

Help build intelligence for Prothena

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Deep pipeline focus on high-unmet-need neurology (Parkinson's) and rare amyloidosis with two Phase 3 programs (Prasinezumab, Birtamimab/NEOD001) nearing potential regulatory inflection points
Strong cash position ($619M) and 68% revenue growth YoY ($54M to $91M FY24-25) indicate runway for continued R&D investment and hiring in core scientific roles
Monoclonal antibody expertise in complex targets (alpha-synuclein, transthyretin amyloid) offers specialized technical skill development rare in mid-cap biotech

Watch Out For

Recent June 2025 layoff of 91 CA-based employees signals restructuring pressures despite revenue growth, suggesting volatility in non-core functions
Negative net income of -$147M in FY25 and burn rate of $221M R&D spending against $91M revenue indicates company is pre-profitability and dependent on pipeline success for long-term viability

Generated by Claude from Prothena's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

non-interventional

AL Amyloidosis

N/A

Clinical Trials (1)

NCT02574676Quality of Life (QOL) Registry for Patients With AL Amyloidosis

N/A

PRX003

Psoriasis

PHASE_1

Clinical Trials (1)

NCT02458677Single Ascending Dose Study of PRX003 in Healthy Subjects

Phase 1

PRX004

Amyloidogenic Transthyretin (ATTR) Amyloidosis

PHASE_1

Clinical Trials (1)

NCT03336580A Study of PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis

Phase 1

PRX002

Parkinson's Disease

PHASE_1

PRX002

Parkinson's Disease

PHASE_1

PRX003

Psoriasis

PHASE_1

Clinical Trials (1)

NCT02630901Multiple Ascending Dose Study of PRX003 in Subjects With Psoriasis

Phase 1

PRX019

Healthy Participants Study

PHASE_1

Clinical Trials (1)

NCT06699680Phase 1 Study of PRX019 in Healthy Adult Volunteers

Phase 1

NEOD001

Primary Amyloidosis

PHASE_1_2

Clinical Trials (1)

NCT01707264Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

Phase 1/2

NEOD001

AL Amyloidosis

PHASE_2

Clinical Trials (1)

NCT02632786The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis

Phase 2

NEOD001

AL Amyloidosis

PHASE_2

Clinical Trials (1)

NCT02613182Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

Phase 2

NEOD001

AL Amyloidosis

PHASE_2

Clinical Trials (1)

NCT03154047Study in Subjects With Light Chain (AL) Amyloidosis

Phase 2

RO7046015

Parkinson's Disease

PHASE_2

Prasinezumab

Parkinsons Disease

PHASE_2

Prasinezumab

Parkinson's Disease

PHASE_3

NEOD001

Primary Systemic (AL) Amyloidosis

PHASE_3

Clinical Trials (1)

NCT02312206The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis

Phase 3

Birtamimab

Light Chain (AL) Amyloidosis

PHASE_3

Clinical Trials (1)

NCT04973137A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 12 clinical trials

Top TAs: Immunology, Neurology

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Immunology

2 pipeline

Neurology

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$91M70%

R&D Spend

$221M(241%)63%

Net Income

-$147M

Risk Signals

WARN Act Layoff Notices (1)

2025-06-02

91 employees affected— CA

Source: state DOL filings, aggregated via Big Local News

June 2025 layoff amendment affected 91 employees in California, signaling cost reduction amid preclinical stage company transitioning pipeline programs.

Active restructuring despite revenue growth suggests internal strategic reassessment; external candidates should expect competitive hiring freezes until Phase 3 milestones resolve.

Prothena(PRTA)

About Prothena

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Recent News · Prothena(5)

Open Jobs (0)

Financials (FY2025)

Risk Signals

WARN Act Layoff Notices (1)